Low-intensity pulsed ultrasound

Wearable Ultrasounds Poised to Revolutionize Healing and Pain Management Healthcare Market

Retrieved on: 
Tuesday, June 29, 2021

The result, Sustained Acoustic Medicine (sam), was found to be capable of altering the trajectory of soft tissue cells to stimulate remodeling and healing.

Key Points: 
  • The result, Sustained Acoustic Medicine (sam), was found to be capable of altering the trajectory of soft tissue cells to stimulate remodeling and healing.
  • Initially commercialized for the veterinary market in 2010, the company's productULTROZwas used to heal soft tissue injuries in dogs and horses.
  • By 2014, ZetrOZ had pivoted to exclusively serve the human market, building on an existing low-intensity pulsed ultrasound medical technology called Exogen.
  • Their flagship product, sam, is an in-home, ultrasound treatment that reduces the need for pain medication and surgery.

Bioventus Recognizes 25 Years of Proven Bone Healing from EXOGEN

Retrieved on: 
Monday, February 24, 2020

Bioventus , a global leader in orthobiologic solutions, is recognizing 25 years of proven bone healing with its EXOGEN Ultrasound Bone Healing System .

Key Points: 
  • Bioventus , a global leader in orthobiologic solutions, is recognizing 25 years of proven bone healing with its EXOGEN Ultrasound Bone Healing System .
  • EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the bodys natural bone healing process and promote fracture healing.
  • The numbers tell such a compelling story and represent an incredible milestone for Bioventus and EXOGEN, said Tony Bihl, CEO, Bioventus.
  • Bioventus, the Bioventus logo, and EXOGEN are registered trademarks of Bioventus LLC.

Bioventus Updates US Label for EXOGEN® Ultrasound Bone Healing System

Retrieved on: 
Monday, February 10, 2020

Bioventus , a global leader in orthobiologic solutions, has updated the indications for use for its EXOGEN Ultrasound Bone Healing System .

Key Points: 
  • Bioventus , a global leader in orthobiologic solutions, has updated the indications for use for its EXOGEN Ultrasound Bone Healing System .
  • EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the bodys natural bone healing process and promote fracture healing.
  • View the full release here: https://www.businesswire.com/news/home/20200210005036/en/
    EXOGEN Ultrasound Bone Healing System from Bioventus (Photo: Business Wire)
    The updated label now prominently features indications for using EXOGEN as an adjunctive non-invasive treatment of established nonunions in patients:
    This label update underscores important usage scenarios where fracture management protocol may have limited consideration.
  • Patients with comorbidities such as osteoporosis and bone infection can benefit from use of EXOGEN by helping to progress fracture healing and resolve nonunion.

National Institute for Health and Clinical Excellence Maintains Previous Recommendation for EXOGEN® Ultrasound Bone Healing System

Retrieved on: 
Tuesday, October 8, 2019

Bioventus , a global leader in orthobiologic solutions, has received notice from the United Kingdoms National Institute for Health and Clinical Excellence (NICE) that it has updated its guidance (MTG12) regarding the use of the EXOGEN Ultrasound Bone Healing System for treatment of long bone fractures with nonunion.

Key Points: 
  • Bioventus , a global leader in orthobiologic solutions, has received notice from the United Kingdoms National Institute for Health and Clinical Excellence (NICE) that it has updated its guidance (MTG12) regarding the use of the EXOGEN Ultrasound Bone Healing System for treatment of long bone fractures with nonunion.
  • EXOGEN uses low-intensity pulsed ultrasound (LIPUS) to help stimulate the bodys natural bone healing process and promote fracture healing.
  • 1 It also has an 86% heal rate for fractures not healing on their own 2 and provides 38% faster healing of fresh fractures.
  • EXOGEN has been a proven alternative to patients seeking to heal long bone nonunion fractures and avoid surgery for many years, said Tony Bihl, CEO, Bioventus.